Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 2/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 4/20 | 0.45 |
| ▸ | BRAF | P15056 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420081 | 0.90 | TRPV1 (0.52) | DDR1NPY2RCSF1R | |
| SCHEMBL1420819 | 0.89 | NPY2R (0.53) | NPY2RRAF1BRAFRAB9ACSF1R | |
| SCHEMBL1420450 | 0.88 | NPY2R (0.54) | NPY2RRAF1BRAFRAB9ACSF1R | |
| SCHEMBL1420117 | 0.87 | LMNA (0.49) | NPY2RRAF1BRAFNPC1RAB9A | |
| SCHEMBL1420605 | 0.86 | NPY2R (0.51) | DDR1NPY2RNPY5RRAF1BRAF | |
| SCHEMBL1420152 | 0.86 | L3MBTL3 (0.47) | NPY2RRAF1BRAFCSF1RNTRK1 | |
| SCHEMBL1420411 | 0.85 | NPY2R (0.52) | DDR1NPY2RNPY5RRAF1BRAF | |
| SCHEMBL1420041 | 0.84 | RHOA (0.53) | NPY2RRAF1BRAFCSF1RNTRK1 | |
| SCHEMBL1420533 | 0.84 | TRPV4 (0.57) | NPY2RRAF1BRAFNPC1RAB9A | |
| SCHEMBL1961881 | 0.84 | CSF1R (0.47) | DDR1NPY2RRAF1BRAFCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | claimed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | G6PD, DHFR, SGMS1 | DDR1 4834/4885NPY2R 4064/4885NPY5R 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.